Abstract

Background. Modern therapeutic options for the treatment of COVID-19 combine the use of drugs that affect both the virus itself and the components of the body's immune response. Despite the fact that the pathogenetic mechanisms of the infectious disease have been partially investigated, treatment methods still do not live up to expectations, which is largely due to the development of adverse drug reactions and conflicting treatment results. This situation necessitates the analysis of modern scientific sources regarding the prospects, advantages and disadvantages of the use of virus-neutralizing monoclonal antibodies, natural killers, mesenchymal stem cells and monoclonal antibodies to interleukin-6. Aim: to examine the present studies on monoclonal antibodies used in treatment of severe cases of coronavirus disease caused by SARS-CoV-2 and to mark it benefits. Materials and methods. The article uses the bibliographic method and is a review of existing works on PubMed and Google Scholar. Results. Data on the presence of neutralizing antibodies in the blood plasma of sick patients gave an impetus to obtaining humanized or fully human monoclonal antibodies, potentially able to become the basis for the development of drugs for the targeted therapy of SARS-CoV-2. When using biological therapy, the maximum selectivity of the impact on the immune system is created, which makes it possible to eliminate one of the links of the pathogenetic chain without significantly affecting the cells of other organs and systems. Also, the possibility of requalification of existing drugs for cell therapy is being considered. Conclusions. Thus, strategies involving the use of virus-neutralizing monoclonal antibodies, natural killers, mesenchymal stem cells, and monoclonal antibodies to interleukin-6 are promising in the treatment of patients with COVID-19